HealthQuill Gensaic Inc.
Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s technology to discover tissue-targeting molecules.
Drugs Medical Pharma

Novo Nordisk to pay US-based Gensaic $354 million upfront in licensing deal

HQ Team March 5, 2025: Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s.

Read More